Clot-Buster Ultrasound Device May Become Best Treatment Option for Stroke Patients
By HospiMedica International staff writers Posted on 01 Sep 2014 |
Image: UAMS researcher William Culp, MD, (right), and Doug Wilson of UALR (left) have developed a device to treat stroke (Photo courtesy of UAMS/UALR Office of Communications).
A new device is being developed to treat stroke more effectively. The new technology fits on the head similar to a halo and delivers therapy to rapidly bust clots that cause stroke.
The device was developed by William Culp, MD, professor of radiology, surgery and neurology and vice chairman of research at the University of Arkansas for Medical Sciences (UAMS; Little Rock, USA), and Dr. Doug Wilson, assistant director at the Graduate Institute of Technology at UALR. One feature of Dr. Culp’s research included using ultrasound scanning in combination with the clot-busting drug tissue plasminogen activator (t-PA).
While studying the treatment to dissolve clots in blood vessels, Dr. Culp realized one problem is getting the ultrasound to operate through the skull. Ultrasound can be delivered anywhere in a patient’s body unless the waves hit something hard similar to bone or something very soft, similar to air. “We realized we had trouble delivering ultrasound to the vessels at the base of the brain,” Dr. Culp stated. “The skull stopped the ultrasounds.”
Dr. Culp collaborated with Dr. Wilson to devise strategies about how to get the ultrasound waves to reach the clot in stroke patients. “This is a great example of how faculty at both schools can partner to develop new technologies. The success of this research will foster ties between the two campuses,” Dr. Wilson said. “It makes me extremely proud to have contributed to a product with potential to help many people,” he said.
Dr. Culp received a grant from UAMS that provided him with the materials he needed to experiment. Wilson and Culp completed their first patent for “ultrasound for augmented clot lysis” in 2005. The patent was licensed in 2006 and has been in development by Cerevast Therapeutics (Redmond, WA, USA).
The ClotBust ER has 16 transducers distributed around the inside—designed to line up with the thin points in the skull: the temples and the foramen magnum in the base of the skull. This allows the ultrasound waves to move through the brain without interruption. After the patient is administered an intravenous (IV) solution containing t-PA, the circular device is positioned onto the patient’s head like a sports visor or halo. “The idea is to deliver ultrasound wherever the clot is and where the IV t-PA is working,” Dr. Culp said. “It makes t-PA work better—improving the clot-busting drug by 40% or 50%. It’s like taking a cooking pot and stirring it. The ultrasound stirs the drug around, making it work better.” The clot disappears more rapidly. “If we resupply blood, we resupply oxygen. The brain recovers quicker. Quicker is, of course, better,” Dr. Culp said.
Now in a phase three human trial, the ClotBust ER has been tested in more than 300 patients. None of the results have come back with substantial adverse effects. Since the trial periods began, 66 other university sites have signed up to be included in the testing. The device will also soon be available at some sites of the statewide stroke network called AR SAVES while it is in trial.
“Our goal is to test 840 patients,” Dr. Culp said. “But right now, the results are looking so promising that it is possible testing could be stopped early if the safety committee determines we don’t have to go any further.” He is hopeful the device will be approved by the start of 2016. “We’re here to find a cure,” Dr. Culp said. “This device is just one part of many things. We mustn’t forget prevention.”
Dr. Culp noted that there has been a significant decrease in strokes in the United States and in Arkansas during the past 20 years. This is especially good news for the state Arkansas, which ranks highest in the United States for rate of stroke deaths. Dr. Culp believes Americans generally now have a better awareness of the disease. “But for those 800,000 people who will have a stroke in the United States every year, we still have to have good therapy,” Dr. Culp concluded. “This device may well be the next step.”
Related Links:
University of Arkansas for Medical Sciences
Cerevast Therapeutics
The device was developed by William Culp, MD, professor of radiology, surgery and neurology and vice chairman of research at the University of Arkansas for Medical Sciences (UAMS; Little Rock, USA), and Dr. Doug Wilson, assistant director at the Graduate Institute of Technology at UALR. One feature of Dr. Culp’s research included using ultrasound scanning in combination with the clot-busting drug tissue plasminogen activator (t-PA).
While studying the treatment to dissolve clots in blood vessels, Dr. Culp realized one problem is getting the ultrasound to operate through the skull. Ultrasound can be delivered anywhere in a patient’s body unless the waves hit something hard similar to bone or something very soft, similar to air. “We realized we had trouble delivering ultrasound to the vessels at the base of the brain,” Dr. Culp stated. “The skull stopped the ultrasounds.”
Dr. Culp collaborated with Dr. Wilson to devise strategies about how to get the ultrasound waves to reach the clot in stroke patients. “This is a great example of how faculty at both schools can partner to develop new technologies. The success of this research will foster ties between the two campuses,” Dr. Wilson said. “It makes me extremely proud to have contributed to a product with potential to help many people,” he said.
Dr. Culp received a grant from UAMS that provided him with the materials he needed to experiment. Wilson and Culp completed their first patent for “ultrasound for augmented clot lysis” in 2005. The patent was licensed in 2006 and has been in development by Cerevast Therapeutics (Redmond, WA, USA).
The ClotBust ER has 16 transducers distributed around the inside—designed to line up with the thin points in the skull: the temples and the foramen magnum in the base of the skull. This allows the ultrasound waves to move through the brain without interruption. After the patient is administered an intravenous (IV) solution containing t-PA, the circular device is positioned onto the patient’s head like a sports visor or halo. “The idea is to deliver ultrasound wherever the clot is and where the IV t-PA is working,” Dr. Culp said. “It makes t-PA work better—improving the clot-busting drug by 40% or 50%. It’s like taking a cooking pot and stirring it. The ultrasound stirs the drug around, making it work better.” The clot disappears more rapidly. “If we resupply blood, we resupply oxygen. The brain recovers quicker. Quicker is, of course, better,” Dr. Culp said.
Now in a phase three human trial, the ClotBust ER has been tested in more than 300 patients. None of the results have come back with substantial adverse effects. Since the trial periods began, 66 other university sites have signed up to be included in the testing. The device will also soon be available at some sites of the statewide stroke network called AR SAVES while it is in trial.
“Our goal is to test 840 patients,” Dr. Culp said. “But right now, the results are looking so promising that it is possible testing could be stopped early if the safety committee determines we don’t have to go any further.” He is hopeful the device will be approved by the start of 2016. “We’re here to find a cure,” Dr. Culp said. “This device is just one part of many things. We mustn’t forget prevention.”
Dr. Culp noted that there has been a significant decrease in strokes in the United States and in Arkansas during the past 20 years. This is especially good news for the state Arkansas, which ranks highest in the United States for rate of stroke deaths. Dr. Culp believes Americans generally now have a better awareness of the disease. “But for those 800,000 people who will have a stroke in the United States every year, we still have to have good therapy,” Dr. Culp concluded. “This device may well be the next step.”
Related Links:
University of Arkansas for Medical Sciences
Cerevast Therapeutics
Latest Surgical Techniques News
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery